Dear Editor,Intra-class switching among interleukin-17 (IL-17) inhibi-tors is common in psoriatic patients experiencing biologi-cal drugs loss of efficacy (LoE). Unlike secukinumab andixekizumab, which target IL-17A, brodalumab inhibits theIL-17 receptor subunit A (IL-17RA), blocking multiple IL-17isoforms; thereby, it potentially offers a therapeutic alterna-tive in patients with moderate-to-severe psoriasis unrespon-sive to IL-17A inhibitors (IL-17Ais)
Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study
Gisondi, Paolo;Bellinato, Francesco;
2025-01-01
Abstract
Dear Editor,Intra-class switching among interleukin-17 (IL-17) inhibi-tors is common in psoriatic patients experiencing biologi-cal drugs loss of efficacy (LoE). Unlike secukinumab andixekizumab, which target IL-17A, brodalumab inhibits theIL-17 receptor subunit A (IL-17RA), blocking multiple IL-17isoforms; thereby, it potentially offers a therapeutic alterna-tive in patients with moderate-to-severe psoriasis unrespon-sive to IL-17A inhibitors (IL-17Ais)
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Acad Dermatol Venereol - 2025 - Balestri - Switching to brodalumab after failure of IL‐17A inhibitors in psoriatic patients.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
465.05 kB
Formato
Adobe PDF
|
465.05 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
